

Length of hospital stay for elective electrophysiological procedures: a survey from the European Heart Rhythm Association

Giuseppe Boriani ^{1,2*}, Jacopo F. Imberti ^{1,3}, Francisco Leyva ^{2,4},
Ruben Casado-Arroyo ^{2,5}, Julian Chun ⁶, Frieder Braunschweig ^{2,7},
Maura M. Zylla ^{2,8}, David Duncker ⁹, Michał M. Farkowski ¹⁰,
Helmut Pürerfellner ¹¹, and José L. Merino ¹²

¹Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Via del Pozzo, 71, Modena 41124, Italy; ²mHealth and Health Economics and PROM Committee of EHRA (European Heart Rhythm Association); ³Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy; ⁴Department of Cardiology, Aston Medical Research Institute, Aston Medical School, Aston University, Aston Triangle, Birmingham B4 7ET, UK; ⁵Department of Cardiology, H.U.B.-Hôpital Erasme, Université Libre de Bruxelles, Brussels 1070, Belgium; ⁶Medizinische Klinik III, CCB am Agaplesion Markus Krankenhaus, Frankfurt am Main, Germany; ⁷Department of Medicine; Solna, Karolinska Institutet and ME Cardiology, Karolinska University Hospital, Norrbacka S1:02, Eugeniavägen 27, Stockholm 171 77, Sweden; ⁸Department of Cardiology, Medical University Hospital, Heidelberg, Germany; ⁹Hannover Heart Rhythm Center, Department of Cardiology and Angiology, Hannover Medical School, Hannover 30625, Germany; ¹⁰Department of Cardiology, Ministry of Interior and Administration National Medical Institute, Warsaw, Poland; ¹¹Ordensklinikum Linz Elisabethinen, Interne II/Kardiologie und Interne Intensivmedizin, Fadingerstraße 1, 4020 Linz, Austria; and ¹²Arrhythmia-Robotic Electrophysiology Unit, La Paz University Hospital, IdiPAZ, Universidad Autónoma, Madrid, Spain

Received 2 August 2023; accepted after revision 24 September 2023; online publish-ahead-of-print 4 October 2023

Aims

Electrophysiological (EP) operations that have traditionally involved long hospital lengths of stay (LOS) are now being undertaken as day case procedures. The coronavirus disease-19 pandemic served as an impetus for many centres to shorten LOS for EP procedures. This survey explores LOS for elective EP procedures in the modern era.

Methods and results

An online survey consisting of 27 multiple-choice questions was completed by 245 respondents from 35 countries. With respect to *de novo* cardiac implantable electronic device (CIED) implantations, day case procedures were reported for 79.5% of implantable loop recorders, 13.3% of pacemakers (PMs), 10.4% of implantable cardioverter defibrillators (ICDs), and 10.2% of cardiac resynchronization therapy (CRT) devices. With respect to CIED generator replacements, day case procedures were reported for 61.7% of PMs, 49.2% of ICDs, and 48.2% of CRT devices. With regard to ablations, day case procedures were reported for 5.7% of atrial fibrillation (AF) ablations, 10.7% of left-sided ablations, and 17.5% of right-sided ablations. A LOS \geq 2 days for CIED implantation was reported for 47.7% of PM, 54.5% of ICDs, and 56.9% of CRT devices and for 54.5% of AF ablations, 42.2% of right-sided ablations, and 46.1% of left-sided ablations. Reimbursement (43–56%) and bed availability (20–47%) were reported to have no consistent impact on the organization of elective procedures.

Conclusion


There is a wide variation in the LOS for elective EP procedures. The LOS for some procedures appears disproportionate to their complexity. Neither reimbursement nor bed availability consistently influenced LOS.

* Corresponding author. Tel: +39 0594225836. E-mail address: giuseppe.boriani@unimore.it

© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Graphical Abstract



Keywords

Ablation • Arrhythmia • Implantable defibrillator • Electrophysiology • Pacemaker • EHRA Survey

What's new?

- There are limited data in the literature on the length of stay for in-hospital elective electrophysiology procedures.
- Our survey highlights substantial variations in length of stay for most elective electrophysiology procedures.
- In a substantial proportion of cases, the length of stay appears disproportionately long for the procedure complexity and, perhaps, clinical need.

Introduction

Major advances in the field of device therapy and ablation have been achieved over recent years. Such advances have transformed the management of patients with or at risk of cardiac arrhythmias and heart failure.¹⁻⁸ Improved detection and treatment of electrophysiological (EP) conditions have placed increasing demands on secondary care medicine.⁹⁻¹⁶

The quality of healthcare institutions is measured in terms of the timely delivery of equitable, safe, effective, and personalized treatment of as many patients as possible.¹⁷ With regard to interventions, quality means short waiting times, preferential treatment of those who benefit the most, a high volume of procedures, a high procedural success rate, a low complication rate, and the minimum possible demands on hospital resources. A key factor in this mix is the length of hospital stay (LOS) for interventional procedures.

The coronavirus disease (COVID)-19 pandemic had a dramatic impact on healthcare provision in general, demanding a more efficient delivery of treatment, not least for patients with or at risk of cardiac arrhythmias or cardiac arrest.¹⁸⁻³⁰ During the pandemic, several groups reported

dramatic reductions in the LOS for interventional procedures, borne out of the need to minimize cross-infection and to maximize hospital bed occupancy and other healthcare resources. Despite considerable logistical and reimbursement pressures,³¹⁻³⁴ day case admissions for elective EP procedures became the standard for many centres especially during the pandemic.^{35,36} It is against this background that the Committee on Health Economics of the European Heart Rhythm Association (EHRA) undertook a survey on current LOS for EP procedures.

Methods

Between 16 April 2023 and 7 May 2023, an online anonymous questionnaire was distributed to EHRA members, members of EP working groups, and healthcare professionals working in the field of cardiac arrhythmias using the EHRA infrastructure, website, social media platforms, and e-mail. Non-European countries were not excluded. A total of 2200 invitations were sent. The questionnaire consisted of 27 multiple-choice questions (see [Supplementary material online, Appendix S1](#)). The survey complied with the European General Data Protection Regulation.

Continuous variables are presented as mean \pm standard deviation (SD). The present survey investigated several types of EP procedures, with different degrees of complexity. Therefore, a single centre may perform only some of those. For the purpose of the present analysis, missing data were excluded. Statistical analyses and graphics were performed using SPSS version 24 (IBM Corp.) and Microsoft Excel (version 16.71).

Results

The survey was completed by 245 participants from 35 hospitals from various countries (see [Supplementary material online, Figure S1](#)). As shown in [Supplementary material online, Figure S2](#), participating centres




Figure 1 Length of hospital stay for elective, device-related procedures. CRT-P/D, cardiac resynchronization therapy and pacing/defibrillation; ICD, implantable cardioverter defibrillator; LAAO, left atrial appendage occluder; PM, pacemaker.





Figure 2 Length of hospital stay for elective electrical cardioversions and ablations. AF, atrial fibrillation; AFL, atrial flutter; AV, atrioventricular; ECV, electrical cardioversion; PVCs, premature ventricular complexes; PVI, pulmonary vein isolation; VT, ventricular tachycardia. *Atrioventricular nodal re-entrant tachycardia, AFL, focal right atrial tachycardia, etc. #Atrioventricular re-entrant tachycardia, focal left atrial tachycardia, etc.



included academic public hospitals (49.2%) general public hospitals (30.6%), specialized public hospitals (5.8%), private general hospitals (5.4%), specialized private hospitals (4.5%), and academic private hospitals (4.5%). The volume of yearly activity for respondents' centres is highlighted in [Supplementary material online, Figure S3](#). Reported pacemaker (PM) procedure volumes (number per year) per centre were as follows: >250 in 63.1%; between 101 and 250 in 33.2%; and ≤100 in 3.7%. Implantable cardioverter defibrillator (ICD)/cardiac resynchronization therapy (CRT) device procedure volumes (number per year) per centre were as follows: >250 in 15.8%; between 101 and 250 in 49.2%; and ≤100 in 35%. Ablation procedure volumes (number per year) per centre were as follows: >400 in 32.3%; between 301 and 400 in 14.5%; between 151 and 300 in 35.9%; and ≤150 in 17.3%.

Practice for elective procedures after the coronavirus disease-19 pandemic

Between 64% and 78% of participants reported that the organization of elective pacing and EP procedures had not changed after the COVID-19 pandemic; between 17% and 29% reported a partial change, and between 4% and 11% reported a complete change (see [Supplementary material online, Figure S4](#)).

Cardiac implantable device implantation

As shown in [Figure 1](#), day case procedures were most frequently reported for PM replacements (61.7%), ICD replacements (49.2%), CRT device replacements (48.2%), and implantable loop recorder (ILR) implantations (79.5%). Overnight stays were most frequently reported for left atrial appendage occluder (LAAO) implantation (41.1%).

A 2-day admission was most frequently reported for ICD (44.3%) and CRT-pacing (P) or CRT-defibrillation (D) (42.7%) implantations. A >2-day stay was most frequently reported for lead extraction in non-PM-dependent patients (38.8%) and PM-dependent patients (50.2%) ([Figure 1](#)).

Ablations

With regard to right-sided ablations, left-sided ablations, and atrioventricular (AV) node ablations, the minority (17.5%, 10.7%, and 16.2%, respectively) were undertaken as a day case ([Figure 2](#)). Overnight stays were reported in 40.3%, 43.2%, and 47.2% of cases, respectively. Most atrial fibrillation (AF) ablations (54.5%) involved a ≥2-day stay. For left-sided, endocardial ventricular tachycardia (VT)/premature ventricular complex (PVC) ablations and epicardial VT ablations, a 2-day admission was reported in 41.2% and 37.1%, respectively ([Figure 2](#)).

Reimbursement

Between 43% and 56% of participants reported that reimbursement had no consistent impact on different elective procedures ([Figure 3](#)). A partial influence was reported by 17–24%; a 'substantial influence' by 11–19% and 12–18% reported that it was a key determinant. When considering only respondents reporting no impact of reimbursement practices on elective EP procedures, the reported percentage of procedures performed as day case increased for PM replacements, ICD replacements, CRT device replacements, ILR implants, and right-sided ablations. For other procedures, data did not change significantly as compared with the general assessment including all respondents (see [Supplementary material online, Figures S5 and S6](#)).




Figure 4 Effect of bed availability on the scheduling of elective electrophysiological procedures. AF, atrial fibrillation; AFL, atrial flutter; AV, atrioventricular; CRT-P/D, cardiac resynchronization therapy and pacing/defibrillation; ECV, electrical cardioversion; ICD, implantable cardioverter defibrillator; LAAO, left atrial appendage occluder; PM, pacemaker; PVCs, premature ventricular complexes; PVI, pulmonary vein isolation; RV, right ventricular; VT, ventricular tachycardia. *Atrioventricular nodal re-entrant tachycardia, AFL, focal right atrial tachycardia, etc. #Atrioventricular re-entrant tachycardia, focal left atrial tachycardia, etc.

Bed availability

Bed availability was reported to have no consistent influence on the organization of the following elective procedures: replacements for non-PM-dependent patients (38% of participants), replacements for PM-dependent patients (41%), ICD replacements for PM-dependent patients (37.8%), ILR implantations (47.2%), and electrical cardioversion for AF/atrial flutter (AFL) (40.5%). A partial influence was reported for the following procedures: PM implantations (40.1%), ICD implantations (41.5%), ICD replacements for non-PM-dependent patients (37%), CRT and pacing/defibrillation (CRT-P/D) implantations (42.1%), CRT-P/D replacements for non-PM-dependent patients (37.3%), CRT-P/D replacements for PM-dependent patients (37.3%), right-sided ablations (39.4%), left-sided ablations (37.4%), AV node ablations (38.5%), ablations for AF (37.3%), ablations for right ventricular outflow tract VT or RV PVCs with endocardial approach (36.8%), ablation for left-sided VT or PVCs with endocardial approach (35.2%), ablation for VT with epicardial approach (31.7%), lead extraction in non-PM-dependent patients (35%), lead extraction in PM-dependent patients (34.3%), and implantation of LAAO (36.9%) (Figure 4). When considering only respondents reporting no impact of bed availability on elective EP procedures, the reported percentage of procedures performed as day case increased for PM implants, PM replacements, ICD replacements, CRT device replacements, ILR implants, elective cardioversions for AF, right-sided ablations, and AV node ablations. For other procedures, data did not change significantly as compared with the general assessment including all respondents (see [Supplementary material online, Figures S7 and S8](#)).

Discussion

This is the first survey to explore organizational practices across a broad range of EP procedures in different European countries.

Several salient findings have emerged. First, the majority of cardiac implantable electronic device (CIED) generator changes and ILR implantations were undertaken as a day case. Second, less than 14% of *de novo* CIED implantations were undertaken as a day case. Most involved overnight or longer stays. Third, a substantial proportion of right-sided ablations and AF ablations involved a ≥ 2 -day stay. Fourth, the COVID-19 pandemic appeared not to have changed the organization of EP procedures in most centres. Last, reimbursement and bed availability were reported to have influenced the organization of elective EP procedures.

Cardiac implantable electronic device generator replacement

Whilst nearly two-thirds of PM generator replacements were undertaken as a day case admission, more than half of ICD and CRT device replacements involved a hospital stay of ≥ 1 day. Although some generator replacement procedures are technically complex, the majority should take less than 1 h and post-operative care should perhaps not exceed 2–3 h. Admittedly, we have not quantified procedure timings, actual LOS, nor indeed the logistics of patient movement through hospitals. There may well be very justifiable explanations for a non-day case procedure. For example, some patients undergoing procedures in an afternoon or evening may not be able to go home the same day, particularly if they are elderly or frail.

Cardiac implantable electronic device implantation

With respect to *de novo* CIED implantations, <14% were undertaken as a day case procedure. In this respect, we should consider that some

centres routinely use general anaesthesia, which may lead to longer LOS than a day case. In addition, a post-operative chest X-ray is routine in most centres and this too may prolong LOS. These factors, however, do not apply to ILR implantations, which in this survey exceeded an overnight stay in >20% of cases.

Ablation

Reportedly, up to 54.5% of AF ablations were performed as a ≥ 2 -day admission. These figures are at odds with those reported by high-volume centres participating in randomized controlled trials. They are also at odds with 'real-world' experience of day case AF ablation, reported to have a low complication rate.^{37–43} In this respect, we should consider that AF ablation has growing indications^{44–46} and that recent technological advances have helped to dramatically reduce procedure times.^{3,47–52} Whether such reductions in procedure times have led to commensurate reductions in LOS is unknown.

Other procedures

Whilst 80.3% of elective cardioversions for AF or AFL were performed as a day case, almost 20% involved an admission for ≥ 1 nights. This is perhaps surprising, given the proven feasibility^{53,54} and safety^{55,56} of day case cardioversion. With regard to lead extractions, the overwhelming majority were performed during a hospital stay ≥ 2 days. In this respect, day case lead extraction has been reported for selected patients^{57,58} but most would accept that this relatively high risk procedure requires an extended stay.⁵⁹

Context

A high proportion of participants to this survey were from high-volume centres, a factor of proven association with higher success rates and lower complication rates, for both pacing and ablation procedures.^{1,2,60–64} This may explain the trend⁶⁵ towards a very short hospital stay in cardiac pacing implantations^{66–68} or replacements.⁶⁹ However, even in such centres, LOS for simple procedures, such as device replacements and loop recorder implantations, is in some cases surprisingly long. In this respect, it is noteworthy that the logistics and reimbursement of elective interventions vary across different healthcare systems, and organization of care and reimbursement policies may show an important heterogeneity.^{31,70–78} Rather than prioritizing reimbursement, which may be at the root of the observed variation in LOS, it may be better to focus on patient values, system performance, and outcomes.^{34,53} The fact that a substantial proportion of participants were from Italy raises the possibility that our findings may not be generalizable. However, because of the nature of our data, namely the results of a survey, we cannot draw any comparisons between countries.

Limitations

Selection bias and potential inaccuracy of self-reported data are important limitations of this survey, which was not designed to compare different countries but to give an overall picture of what is current practice across countries. We hope that this may promote further analysis from administrative data sets and, hopefully, prospective audits in different countries, as has already been done for device replacements in Italy⁶⁹ and other EP procedures in the USA.^{37,56,57} However, when analysing data on LOS from real-world practice, it is important to distinguish hospital stay for elective procedures, as analysed in this survey, from hospital stay for acute or chronic conditions requiring EP procedures during the course of the hospitalization, with hospital stay being dependent on much more complex and not standardized factors. Finally, as only 225 out of 2200 invitations were replied, our findings may have some limitations in being a reflection of all centres.

Conclusions

There is a wide variation in LOS for elective EP procedures. In a substantial proportion of cases, the LOS appears disproportionately long for the procedure complexity and, perhaps, clinical need. Further studies are required to address the reported influence of reimbursement practices, bed availability, and other factors on LOS for EP procedures.

Supplementary material

Supplementary material is available at *Europace* online.

Funding

No funding was received for this work.

Conflict of interest: G.B. reported small speaker fees from Bayer, Boehringer Ingelheim, Boston, Daiichi Sankyo, Microport, Janssen, and Sanofi outside of the submitted work. R.C.-A. reported small educational speakers fees from Abbott and Boston Scientific. J.C. reports lecture fees/honoraria, educational grants Boston Scientific, Medtronic, and Biosense Webster outside of the submitted work. M.M.Z. reports lecture fees/honoraria, educational grants, and travel support by Medtronic, Boston Scientific, Bayer Vital, ZOLL CMS, and Pfizer. D.D. received modest lecture honorary fees from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, CVRx, Medtronic, Microport, Pfizer, and Zoll. M.M.F. reports speaker/consultation fees from Medtronic, Abbott, and ZOLL. The other authors did not report conflicts of interest to disclose outside of the submitted work.

Data availability

Data are derived from an anonymous survey and will be available only upon reasonable request to the authors.

References

- Defaye P, Biffi M, El-Chami M, Boveda S, Glikson M, Piccini J et al. Cardiac pacing and lead devices management: 25 years of research at EP *Europace* journal. *Europace* 2023;**25**: euad202.
- Boersma L, Andrade JG, Betts T, Duytschaever M, Pürerfellner H, Santoro F et al. Progress in atrial fibrillation ablation during 25 years of *Europace* journal. *Europace* 2023;**25**: euad244.
- Gunawardene MA, Willems S. Atrial fibrillation progression and the importance of early treatment for improving clinical outcomes. *Europace* 2022;**24**:ii22–i8.
- Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM et al. 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy. *Eur Heart J* 2021;**42**:3427–520.
- Mullens W, Auricchio A, Martens P, Witte K, Cowie MR, Delgado V et al. Optimized implementation of cardiac resynchronization therapy—a call for action for referral and optimization of care. *Europace* 2021;**22**:2349–69.
- Boriani G, De Ponti R, Guerra F, Palmisano P, Zanotto G, D'Onofrio A et al. Sinergy between drugs and devices in the fight against sudden cardiac death and heart failure. *Eur J Prev Cardiol* 2021;**28**:110–23.
- Marijon E, Garcia R, Narayanan K, Karam N, Jouven X. Fighting against sudden cardiac death: need for a paradigm shift—adding near-term prevention and pre-emptive action to long-term prevention. *Eur Heart J* 2022;**43**:1457–64.
- Leyva F, Israel CW, Singh J. Declining risk of sudden cardiac death in heart failure: fact or myth? *Circulation* 2023;**147**:759–67.
- Proietti M, Romiti GF, Vitolo M, Borgi M, Rocco AD, Farcomeni A et al. Epidemiology of subclinical atrial fibrillation in patients with cardiac implantable electronic devices: a systematic review and meta-regression. *Eur J Intern Med* 2022;**103**:84–94.
- Szymanski T, Ashton R, Sekelji S, Petrungraro B, Pollock KG, Sandler B et al. Budget impact analysis of a machine learning algorithm to predict high risk of atrial fibrillation among primary care patients. *Europace* 2022;**24**:1240–7.
- McIntyre WF, Wang J, Benz AP, Johnson L, Connolly SJ, Van Gelder IC et al. Estimated incidence of previously undetected atrial fibrillation on a 14-day continuous electrocardiographic monitor and associated risk of stroke. *Europace* 2022;**24**:1058–64.
- Troisi F, Guida P, Di Monaco A, Quadriani F, Vitulano N, Grimaldi M. Gender-specific association of risk factors in patients who underwent catheter ablation of atrial fibrillation. *J Cardiovasc Med (Hagerstown)* 2021;**22**:901–8.
- Zhou M, Zhao G, Zeng Y, Zhu J, Cheng F, Liang W. Aging and cardiovascular disease: current status and challenges. *Rev Cardiovasc Med* 2022;**23**:135.

14. Zecchin M, Torre M, Carrani E, Sampaolo L, Ciminello E, Ortis B et al. Seventeen-year trend (2001–2017) in pacemaker and implantable cardioverter-defibrillator utilization based on hospital discharge database data: an analysis by age groups. *Eur J Intern Med* 2021;**84**:38–45.
15. Moltrasio M, Iacopino S, Arena G, Pieragnoli P, Molon G, Manfrin M et al. First-line therapy: insights from a real-world analysis of cryoablation in patients with atrial fibrillation. *J Cardiovasc Med (Hagerstown)* 2021;**22**:618–23.
16. Boriani G, Maniadakis N, Auricchio A, Müller-Riemenschneider F, Fattore G, Leyva F et al. Health technology assessment in interventional electrophysiology and device therapy: a position paper of the European Heart Rhythm Association. *Eur Heart J* 2013;**34**:1869–74.
17. Donabedian A. Evaluating the quality of medical care. *Milbank Mem Fund Q* 1966;**44**:166–206.
18. Paris S, Inciardi RM, Lombardi CM, Tomasoni D, Ameri P, Carubelli V et al. Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: results of the cardio-COVID-Italy multicentre study. *Europace* 2021;**23**:1603–11.
19. O'Shea CJ, Middeldorp ME, Thomas G, Harper C, Elliott AD, Ray N et al. Atrial fibrillation burden during the coronavirus disease 2019 pandemic. *Europace* 2021;**23**:1493–501.
20. Arbelo E, Angera I, Trucco E, Rivas-Gándara N, Guerra JM, Bisbal F et al. Reduction in new cardiac electronic device implantations in Catalonia during COVID-19. *Europace* 2021;**23**:456–63.
21. Boriani G, Palmisano P, Guerra F, Bertini M, Zanotto G, Lavalle C et al. Impact of COVID-19 pandemic on the clinical activities related to arrhythmias and electrophysiology in Italy: results of a survey promoted by AIAC (Italian Association of Arrhythmology and Cardiac Pacing). *Intern Emerg Med* 2020;**15**:1445–56.
22. Zorzi A, Mattesi G, Frigo AC, Leoni L, Bertaglia E, De Lazzari M et al. Impact of coronavirus disease 19 outbreak on arrhythmic events and mortality among implantable cardioverter defibrillator patients followed up by remote monitoring: a single center study from the Veneto region of Italy. *J Cardiovasc Med (Hagerstown)* 2022;**23**:546–50.
23. Dell'Erà G, Colombo C, Forleo GB, Curmis A, Marcantoni L, Racheli M et al. Reduction of admissions for urgent and elective pacemaker implant during the COVID-19 outbreak in Northern Italy. *J Cardiovasc Med (Hagerstown)* 2022;**23**:22–7.
24. Zorzi A, Vio R, Rivezzi F, Falzone PV, Giordani AS, Condello C et al. Characteristics and hospital course of patients admitted for acute cardiovascular diseases during the coronavirus disease-19 outbreak. *J Cardiovasc Med (Hagerstown)* 2021;**22**:29–35.
25. Pepera G, Tribali MS, Batalik L, Petrov I, Papatthanasou J. Epidemiology, risk factors and prognosis of cardiovascular disease in the coronavirus disease 2019 (COVID-19) pandemic era: a systematic review. *Rev Cardiovasc Med* 2022;**23**:28.
26. Boriani G, Guerra F, De Ponti R, D'Onofrio A, Accogli M, Bertini M et al. Five waves of COVID-19 pandemic in Italy: results of a national survey evaluating the impact on activities related to arrhythmias, pacing, and electrophysiology promoted by AIAC (Italian Association of Arrhythmology and Cardiac Pacing). *Intern Emerg Med* 2022;**18**:137–49.
27. Satici S, Iyngkaran P, Andrew S, Patil A, Bidargaddi N, Battersby M et al. Rethinking heart failure care and health technologies from early COVID-19 experiences—a narrative review. *Rev Cardiovasc Med* 2021;**22**:105–14.
28. Yasmin F, Shujaiddin SM, Naeem A, Jabean A, Shah SMI, Ochan RK et al. Exploring the impact of the COVID-19 pandemic on provision of cardiology services: a scoping review. *Rev Cardiovasc Med* 2021;**22**:83–95.
29. Schneider M, Altersberger M, Binder C, Hengstenberg C, Binder T. The COVID-19 burden for health care professionals: results of a global survey. *Eur J Intern Med* 2021;**83**:96–8.
30. Berenguera A, Jacques-Aviñó C, Medina-Perucha L, Puente D. Long term consequences of COVID-19. *Eur J Intern Med* 2021;**92**:34–5.
31. Boriani G, Burri H, Mantovani LG, Maniadakis N, Leyva F, Kautzner J et al. Device therapy and hospital reimbursement practices across European countries: a heterogeneous scenario. *Europace* 2011;**13**:ii59–65.
32. Wang P, Vienneau M, Vogeli C, Schiavoni K, Jubelt L, Mendu ML. Reframing value-based care management: beyond cost reduction and toward patient centeredness. *JAMA Health Forum* 2023;**4**:e231502.
33. Kiss A, Kiss N, Váradi B. Do budget constraints limit access to health care? Evidence from PCI treatments in Hungary. *Int J Health Econ Manag* 2023;**23**:281–302.
34. Boriani G, Vitolo M, Svennberg E, Casado-Arroyo R, Merino JL, Leclercq C. Performance-based risk-sharing arrangements for devices and procedures in cardiac electrophysiology: an innovative perspective. *Europace* 2022;**24**:1541–7.
35. Marijon E, Albenque JP, Boveda S, Jacob S, Schmutz M, Bortone A et al. Feasibility and safety of same-day home discharge after radiofrequency catheter ablation. *Am J Cardiol* 2009;**104**:254–8.
36. He H, Datla S, Weight N, Raza S, Lachlan T, Aldhoon B et al. Safety and cost-effectiveness of same-day complex left atrial ablation. *Int J Cardiol* 2021;**322**:170–4.
37. Chu E, Zhang C, Musikantow DR, Turagam MK, Langan N, Sofi A et al. Barriers and financial impact of same-day discharge after atrial fibrillation ablation. *Pacing Clin Electrophysiol* 2021;**44**:711–9.
38. Kowalski M, Parikh V, Salcido JR, Chalfoun N, Albano A, O'Neill PG et al. Same-day discharge after cryoballoon ablation of atrial fibrillation: a multicenter experience. *J Cardiovasc Electrophysiol* 2021;**32**:183–90.
39. Sahashi Y, Kuno T, Tanaka Y, Passman R, Briasoulis A, Malik AH. The 30-day readmission rate of same-day discharge protocol following catheter ablation for atrial fibrillation: a propensity score-matched analysis from National Readmission Database. *Europace* 2022;**24**:755–61.
40. Kawamura I, Kuno T, Sahashi Y, Tanaka Y, Passman R, Briasoulis A et al. Thirty-day readmission rate of same-day discharge protocol after left atrial appendage occlusion: a propensity score-matched analysis from the National Readmission Database. *Heart Rhythm* 2022;**11**:S1547-5271(22)02168-3.
41. König S, Andrade JG, Bollmann A. Administrative data confirm safety of same-day discharge following catheter ablation of atrial fibrillation: all good or is there a fly in the ointment? *Europace* 2022;**24**:701–2.
42. Tang PT, Davies M, Bashir Y, Betts TR, Pedersen M, Rajappan K et al. Efficacy and safety of same-day discharge after atrial fibrillation ablation compared with post-procedural overnight stay: a systematic review and meta-analysis. *Europace* 2022;**24**:1569–84.
43. Farkowski MM, Karlinski M, Barra S, Providencia R, Golicki D, Pytkowski M et al. Effectiveness and safety of a single freeze strategy of cryoballoon ablation of atrial fibrillation: an EHRA systematic review and meta-analysis. *Europace* 2022;**24**:58–69.
44. Wolfes J, Ellermann C, Frommeyer G, Eckardt L. Evidence-based treatment of atrial fibrillation around the globe: comparison of the latest ESC, AHA/ACC/HRS, and CCS guidelines on the management of atrial fibrillation. *Rev Cardiovasc Med* 2022;**23**:56.
45. Imberti JF, Mei DA, Vitolo M, Bonini N, Proietti M, Potpara T et al. Comparing atrial fibrillation guidelines: focus on stroke prevention, bleeding risk assessment and oral anti-coagulant recommendations. *Eur J Intern Med* 2022;**101**:1–7.
46. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 2021;**42**:373–498.
47. Mulder MJ, Kemme MJB, Allaart CP. Radiofrequency ablation to achieve durable pulmonary vein isolation. *Europace* 2022;**24**:874–86.
48. Boersma L. New energy sources and technologies for atrial fibrillation catheter ablation. *Europace* 2022;**24**:ii44–51.
49. Andrea M, Laura B, Elisa F, Sabrina T. Medical therapy, radiofrequency ablation or cryoballoon ablation as first-line treatment for paroxysmal atrial fibrillation: interpreting efficacy through restricted mean survival time and network meta-analysis. *Rev Cardiovasc Med* 2021;**22**:557–61.
50. Imberti JF, Ding WY, Kotalczyk A, Zhang J, Boriani G, Lip G et al. Catheter ablation as first-line treatment for paroxysmal atrial fibrillation: a systematic review and meta-analysis. *Heart* 2021;**107**:1630–6.
51. Razzack AA, Lak HM, Pothuru S, Rahman S, Hassan SA, Hussain N et al. Efficacy and safety of catheter ablation vs antiarrhythmic drugs as initial therapy for management of symptomatic paroxysmal atrial fibrillation: a meta-analysis. *Rev Cardiovasc Med* 2022;**23**:112.
52. Kunis M, Pavlovic N, Velagic V, Hermida JS, Healey S, Arena G et al. Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation. *Europace* 2021;**23**:1033–41.
53. Metzner A, Suling A, Brandes A, Breithardt G, Camm AJ, Crijns HJGM et al. Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST-AFNET 4 trial. *Europace* 2022;**24**:552–64.
54. Schnabel RB, Marinelli EA, Arbelo E, Boriani G, Boveda S, Buckley CM et al. Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference. *Europace* 2023;**25**:6–27.
55. Massaro G, Spagni S, Martignani C, Bettazzoni L, Spadotto A, Ziacchi M et al. Personalizing configuration for atrial fibrillation external electrical cardioversion to improve first shock efficacy. *J Cardiovasc Med (Hagerstown)* 2022;**23**:655–62.
56. Nguyen ST, Belley-Côté EP, Ibrahim O, Um KJ, Lengyel A, Adli T et al. Techniques improving electrical cardioversion success for patients with atrial fibrillation: a systematic review and meta-analysis. *Europace* 2023;**25**:318–30.
57. Atteya G, Alston M, Sweat A, Saleh M, Beldner S, Mitra R et al. Same-day discharge after transvenous lead extraction: feasibility and outcomes. *Europace* 2023;**25**:586–90.
58. Ray JC, Kusumoto F. The transition to value-based care. *J Interv Card Electrophysiol* 2016;**47**:61–8.
59. Diemberger I, Mazzotti A, Giulia MB, Cristian M, Matteo M, Letizia ZM et al. From lead management to implanted patient management: systematic review and meta-analysis of the last 15 years of experience in lead extraction. *Expert Rev Med Devices* 2013;**10**:551–73.
60. Vassilikos VP, Pagourelis ED, Laroche C, Blomström-Lundqvist C, Kautzner J, Maggioni AP et al. Impact of centre volume on atrial fibrillation ablation outcomes in Europe: a report from the ESC EHRA EORP atrial fibrillation ablation long-term (AFA LT) registry. *Europace* 2021;**23**:49–58.

61. Tonchev IR, Nam M CY, Gorelik A, Kumar S, Haqqani H, Sanders P et al. Relationship between procedural volume and complication rates for catheter ablation of atrial fibrillation: a systematic review and meta-analysis. *Europace* 2021;**23**:1024–32.
62. Han HC, Hawkins NM, Pearman CM, Birnie DH, Krahn AD. Epidemiology of cardiac implantable electronic device infections: incidence and risk factors. *Europace* 2021;**23**:iv3–iv10.
63. Boriani G, Proietti M, Bertini M, Diemberger I, Palmisano P, Baccarini S et al. Incidence and predictors of infections and all-cause death in patients with cardiac implantable electronic devices: the Italian nationwide RI-AIAC registry. *J Pers Med* 2022;**12**:91.
64. Ellenbogen KA, Auricchio A, Burri H, Gold MR, Leclercq C, Leyva F et al. The evolving state of cardiac resynchronization therapy and conduction system pacing: 25 years of research at *EP Europace* journal. *Europace* 2023;**25**:eoad168.
65. Gilliard N, Egli Y, Halfon P. A methodology to estimate the potential to move inpatient to one day surgery. *BMC Health Serv Res* 2006;**6**:1–2.
66. Budano C, Garrone P, Castagno D, Bissolino A, Andreis A, Bertolo L et al. Same-day CIED implantation and discharge: is it possible? The E-MOTION trial (Early Mobilization after pacemaker implantaTION). *Int J Cardiol* 2019;**288**:82–6.
67. Archontakis S, Oikonomou E, Sideris K, Laina A, Tirovola D, Paraskevopoulou D et al. Safety of same-day discharge versus overnight stay strategy following cardiac device implantations: a high-volume single-centre experience. *J Interv Card Electrophysiol* 2023;**66**:471–81.
68. Trongtorsak A, Kewcharoen J, Thangjui S, Worapongsatitaya P, Yodsuwan R, Navaravong L. Same-day discharge after implantation of cardiac implantable electronic devices: a systematic review and meta-analysis. *Pacing Clin Electrophysiol* 2021;**44**:1925–33.
69. Palmisano P, Ziacchi M, Belotti G, Rapacciuolo A, Santini L, Stabile G et al. Clinical and organizational management of cardiac implantable electronic device replacements: an Italian survey promoted by AIAC (Italian Association of Arrhythmology and Cardiac Pacing). *J Cardiovasc Med (Hagerstown)* 2019;**20**:531–41.
70. Banks H, Torbica A, Valzania C, Varabyova Y, Prevolnik Rupel V, Taylor RS et al. Five year trends (2008–2012) in cardiac implantable electrical device utilization in five European nations: a case study in cross-country comparisons using administrative databases. *Europace* 2018;**20**:643–53.
71. Hatz MH, Schreyögg J, Torbica A, Boriani G, Blankart CR. Adoption decisions for medical devices in the field of cardiology: results from a European survey. *Health Econ* 2017;**26**:124–44.
72. Torbica A, Banks H, Valzania C, Boriani G, Fattore G. Investigating regional variation of cardiac implantable electrical device implant rates in European healthcare systems: what drives differences? *Health Econ* 2017;**26**:30–45.
73. Valzania C, Torbica A, Tarricone R, Leyva F, Boriani G. Implant rates of cardiac implantable electrical devices in Europe: a systematic literature review. *Health Policy* 2016;**120**:1–15.
74. Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D et al. European Society of Cardiology: cardiovascular disease statistics 2021. *Eur Heart J* 2022;**43**:716–99.
75. Mond HG, Proclemer A. The 11th world survey of cardiac pacing and implantable cardioverter-defibrillators: calendar year 2009—a World Society of Arrhythmia's project. *Pacing Clin Electrophysiol* 2011;**34**:1013–27.
76. Stabile G, Bertaglia E, Guerra F, Palmisano P, Zoni Berisso M, Soldati E et al. Organization and procedures in contemporary catheter ablation centres: data from the 2018 Italian Catheter Ablation Registry. *J Cardiovasc Med (Hagerstown)* 2021;**22**:631–6.
77. Anguera I, Cano Pérez Ó, Bazán V; Collaborators Scar. Spanish catheter ablation registry. 21st official report of the Heart Rhythm Association of the Spanish Society of Cardiology (2021). *Rev Esp Cardiol (Engl Ed)* 2022;**75**:1029–39.
78. Köbe J, Willy K, Senges J, Hochadel M, Kleemann T, Spitzer SG et al. Selection and outcome of implantable cardioverter-defibrillator patients with and without cardiac resynchronization therapy: comparison of 4384 patients from the German Device Registry to randomized controlled trials. *J Cardiovasc Electrophysiol* 2022;**33**:483–92.